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Before clinical trials demonstrated the 
beneﬁts of blood pressure (BP) control, the 
opinion prevailed that hypertension was 
‘essential’ for end-organ perfusion, and that 
BP should not (and could not at the time) be 
lowered. In time, physicians accepted what 
life insurance actuaries had already known, 
that hypertension shortens lives. Evidence-
based guidelines now instruct physicians 
to strictly control BP in high-risk groups. 
Most large-scale clinical trials exclude 
patients with end-stage renal disease, and 
thus guidelines targeting these patients are 
opinion-based and extrapolated from other 
populations. Because it seems reasonable 
that BP control should eﬀectively reduce 
cardiovascular mortality in end-stage renal 
disease patients, most nephrologists attempt 
to follow this advice.
In 2002, the United Kingdom Renal 
Association Standards Committee rec-
ommended that the arbitrarily chosen BP 
standard be <140/90 mm Hg predialy-
sis and <130/80 mm Hg postdialysis.1 In 
2005, the Kidney Disease Outcomes Qual-
ity Initiative (K/DOQI) Work Group on 
cardiovascular disease in dialysis patients 
(United States) agreed.2 These guidelines 
were made in the absence of compelling 
clinical-trial evidence that lowering BP 
reduces mortality in the hemodialysis 
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population. Therefore, both sets of guide-
lines carry a ‘grade C’ strength of recom-
mendation, which states that “clinicians 
should consider following the guidelines 
for eligible patients,” while recognizing 
that “the recommendation is based on 
either weak evidence or on the opinions of 
the Work Group, that the practice might 
improve health outcomes” (our emphasis). 
Because of this uncertainty, there is signiﬁ-
cant controversy surrounding the targeted 
pressure and the best method to achieve it. 
In fact, two other sets of K/DOQI guide-
lines (the 2004 guidelines on hypertension 
in chronic kidney disease and the 2006 
update of hemodialysis adequacy guide-
lines),3,4 do not recommend speciﬁc BP 
targets in hemodialysis patients. Instead, 
the K/DOQI hemodialysis adequacy 
guidelines focus on volume control, dietary 
sodium restriction, and avoidance of high 
dialysate sodium.
The hemodialysis adequacy guide-
lines highlight the importance of limiting 
sodium intake. As is eloquently pointed 
out by Tomson and others, ﬂuid restric-
tion without sodium restriction is worth-
less, because sodium intake drives thirst.5 
The difficulty in this approach remains 
convincing individual patients to alter their 
diet to avoid sodium, which is ubiquitous in 
many diets. While sodium has insidiously 
increased in processed foods, and sodium-
rich ‘fast foods’ have become more readily 
available, dialysis units have also gradually 
increased dialysate sodium concentra-
tions to reduce symptoms of cramping 
and hypotension. This combination of cir-
cumstances makes sodium removal during 
a dialysis session even more diﬃcult.
The currently available alternatives 
using conventional hemodialysis are anti-
hypertensive medications and aggressive 
ultraﬁltration. In the typical dialysis unit, 
ultraﬁltration consists of the removal of 
2–4 liters over 4 hours (or less time), per-
formed in a similar fashion three times 
weekly against variable dialysate sodium 
concentrations. As we have become accus-
tomed to this routine, we have also become 
progressively less aware of the nonphysi-
ologic nature of the dialysis process and 
how this routine developed for logistic and 
economic reasons rather than for optimal 
patient care. The frequent ﬂuid shifts during 
hemodialysis and inability to rapidly com-
pensate can result in intradialytic hypoten-
sion, bolus ﬂuid resuscitation, and inability 
to achieve true dry weight. Because of the 
higher dialysate sodium concentration, the 
amount of sodium removed during dialy-
sis is dependent on convection rather than 
diﬀusion. Depending on the individual 
patient’s serum sodium concentration, the 
dialysate sodium concentration, and the 
volume of ultraﬁltrate, sodium may actu-
ally be gained rather than removed during 
a dialysis session. In those patients who 
are unable or unwilling to comply with 
dietary restrictions, it may be impossible 
to remove the prescribed volume during 
a 4-hour session. These limitations are 
systematic and entrenched in the present 
culture of health-care delivery, but ongoing 
studies may challenge this standard. Fre-
quent nocturnal dialysis may reduce BP 
in a larger percentage of patients, reverse 
left-ventricular hypertrophy, and hopefully 
even improve mortality rates.6
Davenport et al.7 (this issue) investigated 
the eﬀects of these targets on BP control 
and hypotensive events in London dialysis 
units in a 1-week observational study. The 
authors highlight the diﬃculty of achiev-
ing these guideline goals and the cost of 
such achievements. In the 11 units stud-
ied, the practice patterns of individual 
physicians varied widely. Forty-two per-
cent of patients achieved postdialysis BP 
targets, and antihypertensive medications 
may have made the diﬀerence. Units with 
a higher per capita antihypertensive pre-
scription rate also experienced the most 
success in meeting postdialysis BP goals. 
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The price of achieving the targeted pres-
sure may be intradialytic hypotension, as 
centers with a higher percentage of patients 
at BP goal also had a signiﬁcantly higher 
rate of hypotensive episodes, deﬁned as 
intradialytic fluid resuscitation. Many 
more patients probably were treated for 
intradialytic hypotension by simple cessa-
tion of ultraﬁltration, but these data were 
not captured. Because of the observational 
nature of this study, the number of patients 
achieving BP goals also reﬂects a selection 
bias, as patients were not screened on the 
basis of the presence or absence of hyper-
tension and/or need for antihypertensive 
medications. Thus, a signiﬁcant percentage 
of the patients ‘achieving’ the goal BP are 
probably not chronically hypertensive and 
are not in the group targeted for BP reduc-
tion. These subjects may also contribute 
heavily to the number of patients requiring 
intradialytic ﬂuid resuscitation, confound-
ing the argument that trying to achieve the 
BP targets results in hypotension. In our 
opinion, the study does not support the 
guideline targets.
Large observational studies describe a 
U-shaped mortality (Figure 1) curve with 
regard to BP in dialysis patients.8–10 Not 
only do they fail to demonstrate a correla-
tion between worse outcome and signiﬁ-
cant hypertension, but they demonstrate 
increased mortality at lower BP. One such 
study used to support BP targets reveals 
an increased risk of cardiac hypertrophy 
with increasing BP but still demonstrates 
the paradoxically increased mortality 
rate in the lower BP range.11 Quoting the 
authors, “low, not high, BP was associated 
with earlier death independently of age, 
diabetes, ischemic heart disease, anemia 
and hypoalbuminemia.” Because of the 
observational nature of these studies, 
confounding factors leave us uncertain. Is 
the hemodialysis population truly unique 
in that hypertension somehow provides 
protection against dialysis-related adverse 
events? That argument would cast aside 
all the intervention trials in other popula-
tions. On the other hand, there seems to 
be some validity to this argument. Several 
large trials in hemodialysis patients have 
recently failed to show any mortality ben-
efit for rational treatment goals such as 
raising hemoglobin levels, increasing the 
dose of dialysis, and prescribing statins or 
antioxidants.
With the paucity of trial data in the 
guideline-oriented practice of today, the 
work groups are faced with a dilemma. If 
a BP target is absent from the guidelines, 
then hypertension may receive inadequate 
medical attention. If BP targets are set too 
low, then nephrologists may expose their 
patients to an increased risk of intradialytic 
hypotension or other adverse events in an 
attempt to appease oversight committees or 
to attain pay-for-performance rewards.
Furthermore, guidelines based on ‘grade 
C’ strength of recommendation should at 
best be considered only recommendations 
and do not warrant a performance meas-
urement. In proper medical-guideline 
development, risk analyses precede imple-
mentation. The study by Davenport et al.7 
should have been performed before the 
implementation. Eﬀectiveness research is 
critical for any guideline and must address 
the possibility that physicians may not 
execute the recommendations if they do 
not think that the practice will achieve 
the desired goal (a concept called lack of 
expectancy outcome).
If survival is the desired outcome in 
hemodialysis patients, why lower BP? 
Guidelines must not contradict other guide-
lines or cause confusion. We discussed this 
problem above. Taking all these issues into 
account, it becomes clear that we less need 
guidelines on BP control in dialysis patients 
than we need adequately powered clinical 
trials to determine the risks and beneﬁts 
of BP control. The K/DOQI guidelines on 
hemodialysis adequacy have instead taken 
a reasonable approach by excluding any 
BP goals and focusing on patient educa-
tion and prevention of hypertension with 
dietary sodium restriction.
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Figure 1 | Basic relationship of blood pressure (BP) to mortality in dialysis patients, as 
obtained from observational studies.
